Autopsy report · NCT01334710

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

“safety issue observed on another hepatocellular study using OSI906”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Liver Cancer

Interventions

Sorafenib and OSI-906

Participants

3

Sites

3

Countries

United States

Trials that died the same way

• Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
  “Hepatic safety signal identified.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.